文献速递泌尿男性生殖肿瘤

阿维鲁单抗联合阿昔替尼对比舒尼替尼一线治疗晚期肾细胞癌:III期JAVELIN Renal 101试验最终分析

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
PubMed 文献 · Ann Oncol · 2024-12-18

III期JAVELIN Renal 101试验最终分析显示,在晚期肾细胞癌患者中,阿维鲁单抗联合阿昔替尼对比舒尼替尼的总生存期分析倾向于联合组但未达统计学显著;联合组无进展生存期持续延长,客观缓解率接近翻倍,缓解更持久,长期安全性可控。

要点

  • PD-L1阳性人群总生存期联合组43.2个月对比舒尼替尼组36.2个月,HR 0.86,P=0.0755,未达统计学显著。
  • 总体人群客观缓解率联合组59.7%对比舒尼替尼组32.0%,联合组接近翻倍。
  • 总体人群5年无事件率联合组12.0%对比舒尼替尼组4.4%,联合组持续延长。

核心结论

  • JAVELIN Renal 101提供了aRCC中免疫检查点抑制剂联合酪氨酸激酶抑制剂III期试验迄今最长随访。
  • 总生存期分析倾向于阿维鲁单抗联合阿昔替尼对比舒尼替尼但未达统计学显著,后续治疗可能影响结果。
  • 阿维鲁单抗联合阿昔替尼对比舒尼替尼提供长期疗效获益,包括无进展生存期延长、客观缓解率接近翻倍和缓解更持久,长期安全性可控。

研究设计与样本

  • III期JAVELIN Renal 101试验(NCT02684006),入组未经治疗的晚期肾细胞癌患者(任何预后风险评分)。
  • 主要终点为程序性死亡配体1阳性(PD-L1+)人群的总生存期和无进展生存期。

主要发现

  • PD-L1+人群总生存期联合组43.2个月(95%CI 36.5-51.7个月)对比舒尼替尼组36.2个月(95%CI 29.8-44.2个月),HR 0.86(95%CI 0.701-1.057),P=0.0755。
  • 总体人群总生存期联合组44.8个月(95%CI 39.7-51.1个月)对比舒尼替尼组38.9个月(95%CI 31.4-45.2个月),HR 0.88(95%CI 0.749-1.039),P=0.0669。
  • 总体人群5年无事件率联合组12.0%(95%CI 8.9%至15.6%)对比舒尼替尼组4.4%(95%CI 2.5%至7.3%)。
  • 总体人群客观缓解率联合组59.7%(95%CI 55.0%至64.3%)对比舒尼替尼组32.0%(95%CI 27.7%至36.5%)。
  • 缓解持续时间≥5年者联合组16.4%(95%CI 12.0%至21.4%)对比舒尼替尼组9.2%(95%CI 4.6%至15.7%);≥3级治疗相关不良事件发生率联合组66.8%对比舒尼替尼组61.5%;患者报告结局两组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 总生存期分析未达统计学显著。
  • 后续治疗可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase III JAVELIN Renal 101 trial (NCT02684006), first-line treatment with avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) versus sunitinib in patients with advanced renal cell carcinoma (aRCC). We report the final analysis, including the primary analysis of overall survival (OS). PATIENTS AND METHODS: Patients with untreated aRCC (any prognostic risk score) were enrolled. The primary endpoints were OS and PFS in the programmed death-ligand 1-positive (PD-L1+) population. ORR, duration of response, safety, and patient-reported outcomes (PROs) were also assessed. RESULTS: The minimum follow-up was 68 months in all patients. The median OS with avelumab + axitinib versus sunitinib, respectively, was 43.2 months [95% confidence interval (CI) 36.5-51.7 months] versus 36.2 months (95% CI 29.8-44.2 months) in the PD-L1+ population [hazard ratio (HR) 0.86 (95% CI 0.701-1.057); P = 0.0755] and 44.8 months (95% CI 39.7-51.1 months) versus 38.9 months (95% CI 31.4-45.2 months) in the overall population [HR 0.88 (95% CI 0.749-1.039); P = 0.0669]. Investigator-assessed PFS remained prolonged with avelumab + axitinib versus sunitinib [5-year event-free rate in the overall population, 12.0% (95% CI 8.9% to 15.6%) versus 4.4% (95% CI 2.5% to 7.3%)]. ORR in the overall population was 59.7% (95% CI 55.0% to 64.3%) with avelumab + axitinib versus 32.0% (95% CI 27.7% to 36.5%) with sunitinib; duration of response was ≥5 years in 16.4% (95% CI 12.0% to 21.4%) versus 9.2% (95% CI 4.6% to 15.7%), respectively. Rates of grade ≥3 treatment-related adverse events were 66.8% versus 61.5%, respectively. PROs were similar between arms. CONCLUSIONS: JAVELIN Renal 101 provides the longest follow-up to date for immune checkpoint inhibitor + tyrosine kinase inhibitor combination treatment from a phase III trial in aRCC. OS analyses favored avelumab + axitinib versus sunitinib but did not reach statistical significance; subsequent treatment may have impacted results. Avelumab + axitinib provided long-term efficacy benefits versus sunitinib, including prolonged PFS, a nearly doubled ORR, and more durable responses, with a manageable long-term safety profile.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Choueiri TK, Penkov K, Uemura H, et al. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2024. PMID: 39706335. doi:10.1016/j.annonc.2024.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。